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Although several clinical practice guidelines have been produced
for the use of serum tumour markers in the management of breast
cancer, the practice remains inconsistent (ASCO, 1996; ANAES,
1997; Bast et al, 2001; Mauriac et al, 2001). All current knowledge
was therefore reviewed.
OBJECTIVES
The objective was to define the characteristics of breast cancer
tumour markers and identify their potential role in the manage-
ment of patient with cancer. The main question concerns the role
of CA 15-3 (and to a lesser degree that of carcinoembryonic
antigen (CEA)) in the early diagnosis of metastases and loco-
regional recurrence and in evaluation of response to treatment.
These recommendations are intended for both scientists and
clinicians. This document does not cover the clinical indications in
which tumour markers should or can be used. This aspect is
covered in the Standards, Options and Recommendations (SORs)
document on metastatic breast cancer (Mauriac et al, 2001). This
document aims to provide the multidisciplinary team, responsible
for defining the treatment plan, with laboratory data to help them
optimise the management of patients with metastatic breast
cancer.
METHODOLOGY FOR THE DEVELOPMENT OF THE
SORs FOR SERUM TUMOUR MARKERS IN BREAST
CANCER
The general methodology has been previously described (Fervers
et al, 2001). For this particular SOR, a working group of scientists
and clinicians was set up by the National Federation of French
Cancer Centres (Fe ´de ´ration Nationale des Centres de Lutte Contre
le Cancer: FNCLCC) to review the available scientific data for the
use of serum tumour markers in breast cancer. A literature search
of Medline
s, from 1991 to 1998, was updated in 2000. The
members of the working group also provided references from their
personal reference database. The members of the group selected
and critically appraised the papers and then wrote a draft version
of the clinical practice guidelines, the ‘Standards’, ‘Options’ and
Recommendations’ (Fervers et al, 2001) for breast cancer, based on
the available scientific evidence or expert agreement.
‘Standards’ identify clinical situations for which there exist
strong indications or contraindications for a particular interven-
tion and ‘Options’ identify situations for which there are several
alternatives, none of which have shown clear superiority over the
others (Table 1). In any SOR, there can be several ‘Options’ for a
given clinical situation. ‘Recommendations’ enable the ‘Options’t o
be weighted according to the available evidence. Several interven-
tions can be recommended for the same clinical situation, so that
clinicians can make a choice according to specific clinical
parameters, for example, local circumstances, skills, equipment,
resources and patient preferences. Adapting the SORs to a local
situation is possible if the reason for the choice is sufficiently
transparent and this is crucial for successful implementation.
Inclusion of patients in clinical trials is an appropriate form of
patient management in oncology and is recommended frequently
within the SORs, particularly in situations where the evidence is
too weak to support an intervention.
The type of evidence underlying any ‘Standard’, ‘Option’o r
‘Recommendation’ is indicated using a classification developed by
the FNCLCC based on previously published models. The level of
evidence depends not only on the type and quality of the studies
reviewed, but also on the concordance of the results (Table 2).
When no clear scientific evidence exists, judgement is made
according to the professional experience and consensus of the
expert group (‘expert agreement’).
The full document was then reviewed by independent experts
and the final document was validated in April 2000. This summary
version was drafted in January 2001 from the full version (Basuyau
et al, 2000) and both versions are available in French on the
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when new scientific data becomes available or if there is a change
in expert agreement.
SUMMARY OF SORS FOR SERUM TUMOUR MARKERS
IN BREAST CANCER
CA 15.3 and to a lesser extent CEA are the most commonly used
serum tumour markers in breast cancer. If the concentration of CA
15.3 is high at presentation, routine assays of other markers is not
justified (standard, expert agreement). All assays for a given
patient should be performed in the same laboratory, using the
same technique, since results have been shown to be dependant on
the assay technique used (standard, expert agreement). Other
markers, mainly epitopes present on mucin glycoproteins (CA549,
CA M26, CA M29, CA27.29) are under evaluation, but to date none
have been shown to be more useful than CA 15.3. These other
markers may be used instead of CA 15.3, but not in combination.
Role of CA 15.3 assays in the screening and diagnosis of
breast cancer
The assay for CA 15.3 should not be used as a screening or
diagnostic test because of its low sensitivity (standard, level of
evidence: B2). In the diagnosis of metastatic adenocarcinoma of
unknown origin, CA 15.3 is likely to help make the diagnosis and
therefore will have an impact on the treatment plan (option, expert
agreement).
Significance of the initial level of CA 15-3
The pretreatment CA 15.3 level is a recognised prognostic factor,
but it has not been proven to be an independent prognostic factor
(standard, level of evidence: B2).
An initially high CA 15.3 level is more often observed in patients
with advanced cancer than in those with localised cancer
(standard, level of evidence: B2). Several studies have shown that
the concentration is correlated with the disease stage (standard,
level of evidence: B2). If the initial concentration is more than
50kUl
1, a search for metastases should be undertaken before any
treatment plan is decided (standard, expert agreement), particu-
larly if the result of this search will modify treatment.
The pretreatment concentration of CA 15.3 should be con-
sidered as the reference value, in the event of suspected metastatic
recurrence (recommendation, expert agreement).
Prognostic value of a rising CA 15.3 level during the initial
treatment
CA 15.3 levels that are initially high and remain high despite
treatment indicate a failure to respond to treatment and a very
poor prognosis (standard, level of evidence: C).
Early diagnosis of locoregional and/or metastatic
recurrence
The sensitivity of tumour markers in the diagnosis of local
recurrence is poor, but their usefulness (particularly that of CA
15.3) in the early diagnosis of breast cancer metastases is clear
(standard, level of evidence: A).
The early detection of metastatic disease does not benefit the
patient in terms of overall survival or time to the appearance of
clinical signs (standard, level of evidence: C).
Role of tumour markers in the follow-up after treatment
The CA 15.3 level at the time of the diagnosis of metastatic disease
does not seem to be a prognostic factor for treatment response
(standard, level of evidence: C). There is a correlation between
tumour marker levels and disease response during treatment for
metastases (standard, level of evidence: C). The measurement of
CA 15.3 levels during treatment follow-up in patients with
metastatic disease is useful in the evaluation of the treatment
Table 1 Definition of ‘Standards, Options and Recommendations’
Standards Procedures or treatments that are considered to be of benefit, inappropriate or harmful by unanimous decision based on the best available
evidence
Options Procedures or treatments that are considered of to be benefit, inappropriate or harmful by a majority, based on the best available evidence
Recommendations Additional information to enable the available options to be ranked using explicit criteria (e.g., survival, toxicity) with an indication of the
level of evidence
Table 2 Definition of level of evidence
Level A
There exists a high standard meta-analysis on several high standard randomized clinical trials that give consistent results
Level B
There exists good quality evidence from randomised trials (B1) or prospective or restrospective studies (B2). The results are consistent when considered together
Level C
The methodology of the available studies is weak or their results are not consistent when considered together
Level D
Either the scientific data does not exist or there is only a series of cases
Expert agreement
The data does not exist for the method concerned, but the experts are unanimous in their judgement
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Prospective clinical trials using the criteria defined by the Working
Group on Tumor Marker Criteria (Bonfrer, 1990) and evaluating
the rate of change in tumour marker levels should be undertaken
(recommendation, expert agreement).
Combination of different tumour markers
There is no justification for routinely measuring a number of
markers (standard, level of evidence: B2). CA 15.3 remains the
reference marker for breast cancer (standard). Other markers
should only be measured in the setting of a randomised clinical
trial assessing the benefits of the early diagnosis and treatment of
metastases (recommendation, expert agreement).
If the concentration of CA 15.3 remains normal, but there is
obvious clinical progression of disease, alternative indicators for
treatment response should be identified such as CEA, tissue
polypeptide antigen (TPA), or polypeptide-specific antigen (TPS)
(recommendation, expert agreement).
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